Upon nivolumab treatment, widespread up-regulation of CBLB was observed in CD8+ T cells, LAIR2+ γδ T cells, and LAIR2+ TEMs, suggesting that the most tumor-reactive immune cell subtypes were affected (Fig. 5B and fig. The gene discussed is CD8A; the disease is neoplasm.